Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry

10.32% CAGR in Chemiluminescence Immunoassay Analyzers Market | Increasing Prevalence of Acute and Chronic Diseases | Technavio

PR Newswire ·  {{timeTz}}

NEW YORK, Nov. 29, 2021 /PRNewswire/ -- The chemiluminescence immunoassay analyzers market size is anticipated to grow by USD 3.24 bn, progressing at a CAGR of 10.32%. This market forecast report provides a detailed customer landscape matrix comparing key industry-driven parameters.

Read Our Free Sample to explore growth opportunities in the chemiluminescence immunoassay (CLIA) analyzers market

Chemiluminescence Immunoassay Analyzers Market by End-user and Geography - Forecast and Analysis 2022-2026 Research Report is now Available at Technavio

Market Dynamics

The market is driven by factors such as the higher sensitivity and accuracy of CLA over ELISA, increasing prevalence of acute and chronic diseases, and the predictive and preventive medicine for early diagnosis and treatment. However, lack of trained professionals and stringent regulation and policies are expected to reduce the growth potential of the market.

For additional information on the various trends, drivers, and challenges impacting the market, View a Free Sample Report Now

Company Profiles

Some of the companies covered in this report are Abbott Laboratories, Beckman Coulter Inc., Chengdu Seamaty Technology Co. Ltd., F. Hoffmann-La Roche Ltd., PerkinElmer Inc., Shenzhen Mindray Bio-Medical Electronics Co. Ltd., Shenzhen New Industries Biomedical Engineering Co. Ltd., Siemens AG, Sysmex Corp., and Tosoh Corp.

Competitive Analysis

The report includes the competitive analysis, a proprietary tool to analyze and evaluate the position of companies based on their industry position score and market performance score. The tool uses various factors for categorizing the players into four categories. Some of these factors considered for analysis are financial performance over the last 3 years, growth strategies, innovation score, new product launches, investments, growth in market share, etc.

Market Segmentation

  • By end-user, the market is classified into hospitals, clinical laboratories, PBC, and others. The hospitals segment will contribute the largest share of the market.
  • By geography, the market is classified into North America, Europe, Asia, and ROW. North America will have the largest share of the market.

Subscribe to our "Lite Plan" billed annually at USD 3000 to view 3 reports monthly and download 3 reports annually.

Related Reports:

  • External Nasal Dilator Market: The external nasal dilator market has been segmented by end-user (adults and pediatrics), application (nasal congestion, snoring, and others), and geography (North America, Europe, Asia, and ROW). Download Free Sample Report
  • Surgical Instruments Market: The surgical instruments market has been segmented by product (surgical sutures and stapling devices, handheld surgical devices, and electrosurgical devices) and geography (North America, Asia, Europe, and ROW). Download Free Sample Report

Chemiluminescence Immunoassay Analyzers Market Scope

Report Coverage

Details

Page number

120

Base year

2021

Forecast period

2022-2026

Growth momentum & CAGR

Accelerate at a CAGR of 10.32%

Market growth 2022-2026

USD 3.24 billion

Market structure

Fragmented

YoY growth (%)

9.38

Regional analysis

North America, Europe, Asia, and ROW

Performing market contribution

North America at 35%

Key consumer countries

US, UK, Canada, Germany, and France

Competitive landscape

Leading companies, competitive strategies, consumer engagement scope

Companies profiled

Abbott Laboratories, Beckman Coulter Inc., Chengdu Seamaty Technology Co. Ltd., F. Hoffmann-La Roche Ltd., PerkinElmer Inc., Shenzhen Mindray Bio-Medical Electronics Co. Ltd., Shenzhen New Industries Biomedical Engineering Co. Ltd., Siemens AG, Sysmex Corp., and Tosoh Corp.

Market Dynamics

Parent market analysis, market growth inducers and obstacles, fast-growing and slow-growing segment analysis, COVID-19 impact and future consumer dynamics, market condition analysis for the forecast period

Customization purview

If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

About Us

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contact

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/

SOURCE Technavio

This presentation is for informational and educational use only and is not a recommendation or endorsement of any particular investment or investment strategy. Investment information provided in this content is general in nature, strictly for illustrative purposes, and may not be appropriate for all investors. It is provided without respect to individual investors’ financial sophistication, financial situation, investment objectives, investing time horizon, or risk tolerance. You should consider the appropriateness of this information having regard to your relevant personal circumstances before making any investment decisions. Past investment performance does not indicate or guarantee future success. Returns will vary, and all investments carry risks, including loss of principal. Moomoo makes no representation or warranty as to its adequacy, completeness, accuracy or timeliness for any particular purpose of the above content.

Moomoo is a financial information and trading app offered by Moomoo Technologies Inc.
In the U.S., investment products and services available through the moomoo app are offered by Moomoo Financial Inc., a broker-dealer registered with the U.S. Securities and Exchange Commission (SEC) and a member of Financial Industry Regulatory Authority (FINRA)/Securities Investor Protection Corporation (SIPC).
In Singapore, investment products and services available through the moomoo app are offered through Moomoo Financial Singapore Pte. Ltd. regulated by the Monetary Authority of Singapore (MAS). Moomoo Financial Singapore Pte. Ltd. is a Capital Markets Services Licence (License No. CMS101000) holder with the Exempt Financial Adviser Status. This advertisement has not been reviewed by the Monetary Authority of Singapore.
In Australia, financial products and services available through the moomoo app are provided by Futu Securities (Australia) Ltd, an Australian Financial Services Licensee (AFSL No. 224663) regulated by the Australian Securities and Investment Commission (ASIC). Please read and understand our Financial Services Guide, Terms and Conditions, Privacy Policy and other disclosure documents which are available on our websites https://www.futuau.com and https://www.moomoo.com/au. Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd. and Futu Securities (Australia) Ltd are affiliated companies.